Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more
Imugene Limited (IUGNF) - Total Assets
Latest total assets as of June 2025: $83.59 Million USD
Based on the latest financial reports, Imugene Limited (IUGNF) holds total assets worth $83.59 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Imugene Limited - Total Assets Trend (1993–2025)
This chart illustrates how Imugene Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Imugene Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Imugene Limited's total assets of $83.59 Million consist of 49.9% current assets and 50.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.2% |
| Accounts Receivable | $10.02 Million | 12.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $31.69 Million | 37.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Imugene Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imugene Limited's current assets represent 49.9% of total assets in 2025, an increase from 2.9% in 1993.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2025, up from 0.3% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, a decrease from 70.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 37.9% of total assets.
Imugene Limited Competitors by Total Assets
Key competitors of Imugene Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Imugene Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Imugene Limited generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Imugene Limited is currently not profitable relative to its asset base.
Imugene Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 3.86 | 11.90 |
| Quick Ratio | 1.88 | 3.93 | 11.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.59 Million | $ 83.74 Million | $ 31.60 Million |
Imugene Limited - Advanced Valuation Insights
This section examines the relationship between Imugene Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -44.8% |
| Total Assets | $83.59 Million |
| Market Capitalization | $4.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imugene Limited's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Imugene Limited's assets decreased by 44.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imugene Limited (1993–2025)
The table below shows the annual total assets of Imugene Limited from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $83.59 Million | -44.79% |
| 2024-06-30 | $151.40 Million | -23.17% |
| 2023-06-30 | $197.06 Million | +33.51% |
| 2022-06-30 | $147.61 Million | +105.55% |
| 2021-06-30 | $71.81 Million | +10.13% |
| 2020-06-30 | $65.20 Million | +111.85% |
| 2019-06-30 | $30.78 Million | +81.97% |
| 2018-06-30 | $16.91 Million | +33.42% |
| 2017-06-30 | $12.68 Million | +32.95% |
| 2016-06-30 | $9.54 Million | +4.62% |
| 2015-06-30 | $9.11 Million | +5.60% |
| 2014-06-30 | $8.63 Million | +233.97% |
| 2013-06-30 | $2.58 Million | +96.03% |
| 2012-06-30 | $1.32 Million | -71.87% |
| 2011-06-30 | $4.69 Million | +14.36% |
| 2010-06-30 | $4.10 Million | -28.88% |
| 2009-06-30 | $5.76 Million | +11.61% |
| 2008-06-30 | $5.16 Million | -1.84% |
| 2007-06-30 | $5.26 Million | -27.63% |
| 2006-06-30 | $7.27 Million | -19.81% |
| 2005-06-30 | $9.06 Million | +50.67% |
| 2004-06-30 | $6.02 Million | -26.13% |
| 2003-06-30 | $8.14 Million | +864.49% |
| 2002-06-30 | $844.39K | -65.40% |
| 2001-06-30 | $2.44 Million | -33.72% |
| 2000-06-30 | $3.68 Million | -46.58% |
| 1999-06-30 | $6.89 Million | -12.65% |
| 1998-06-30 | $7.89 Million | -9.23% |
| 1997-06-30 | $8.69 Million | -6.01% |
| 1996-06-30 | $9.25 Million | -22.45% |
| 1995-06-30 | $11.93 Million | +5.42% |
| 1994-06-30 | $11.31 Million | +98.54% |
| 1993-06-30 | $5.70 Million | -- |